Epizyme, Inc. was a big mover last session, as the company saw its shares rise over 17% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 10.2% in the past one-month time frame.

The stock gained after the company announced positive interim data from an ongoing phase II study evaluating tazemetostat in lymphoma at the International Conference on Malignant Lymphoma.

The company has seen two positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Epizyme. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Epizyme currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Epizyme, Inc. Price and Consensus

A better-ranked stock in the Zacks categorized Medical - Biomedical and Genetics industry is VIVUS, Inc. , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is EPZM going up? Or down? Predict to see what others think: Up or Down

3 Top Picks to Ride the Hottest Tech Trend

Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...

Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>